Chimeric Therapeutics (ASX:CHM) said that the University of Chicago Medicine will enroll patients in its multi-center phase one/two clinical trial for its anti-CDH17 chimeric antigen receptor T-cell therapy, according to a Monday Australian bourse filing.
The trial is a two-stage study to determine a recommended phase two dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.
CHM CDH17 is a CAR T-cell therapy, a type of immunotherapy, that targets CDH17, a cancer target associated with poor prognosis and metastases in the most common gastrointestinal tumors, the filing said.
The first phase of the study is expected to enroll 15 patients.
Its shares rose 14% on market close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.